Printer Friendly

Kamada Begins Phase I Clinical Trials of Its Aerosolized API Treatment for Congenital Emphysema.

Joint clinical Development Agreement signed with PARI

NESS ZIONA, Israel -- Kamada (TASE:KMDA), a bio-pharmaceutical company engaged in the development, manufacturing and marketing of prescription medicines, announced today that it has begun human Phase I trials of an inhaled formulation of its flagship drug, Alpha 1-Proteinase Inhibitor (API). The trials will examine the product's safety on approximately 20 participants and will continue for several months according to a plan approved by the EMEA, the European Agency for Evaluation of Medicinal Products.

Kamada has also signed a strategic agreement with PARI, a Germany-based world leader in aerosol therapies, for the conjoint clinical development and marketing of API administered by inhalation.

Under the agreement, PARI grants Kamada the exclusive license to use PARI's eFlow Electronic Nebulizer for clinical trials and to commercialize Kamada's API with the eFlow device, including marketing and distribution.

PARI will further develop the eFlow and provide technical and regulatory support throughout the clinical trials and the registration process, until final approvals are received from the regulatory authorities. Kamada will supply the API drug product required for the clinical trials.

Kamada CEO David Tsur stated, "By enabling the penetration of a new market for its API, this agreement marks a milestone for Kamada. The respiratory form of API also represents a revolution in treatment as it provides the patient with a much higher level of comfort. It also has considerable financial advantages, since a much lower dose is required compared to the infused version, enabling the treatment of a greater number of patients."

"We are excited to extend our collaboration for the long term with Kamada, the leading producer of a highly purified, ready-to-use injectable API, to develop it as an inhaled treatment for congenital emphysema," said Dr. Martin Knoch, Managing Director of PARI. "We believe this could be a substantial improvement for patients and a perfect example of how eFlow can contribute to a more efficient and convenient therapy."

"Kamada's API holds Orphan Drug Designation for the treatment of Congenital Emphysema and Cystic Fibrosis in Europe and the U.S. This designation grants Kamada regulatory support, tax incentives and market exclusivity for 7-10 years, as well as funding to stimulate further research and development, should Kamada reach the market first," added Mr. Tsur.

About Kamada

Kamada is a biopharmaceutical company engaged in the development, production, and marketing of high quality, ready to use, plasma therapeutics. In addition to API, Kamada's product line includes specific and general immune globulins, and other plasma-derived products which are manufactured using sophisticated chromatographic purification technology. Kamada is based in Kiryat Weizmann Science Park, Ness Ziona, Israel.

About eFlow

eFlow, an electronic, portable nebulizer, enables extremely efficient aerosolization of liquid medications via a vibrating, perforated membrane. Compared to other nebulizer systems, eFlow can produce aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, eFlow helps reduce the burden of daily inhalation treatments.

For additional information, please see

About PARI

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's primary focus is to provide patients with innovative products and services that help control disease. PARI is headquartered in Starnberg, Germany, with a major presence in the United States and offices in Japan, the United Kingdom and China.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 27, 2006
Previous Article:USA TODAY Joins Shoom, the Only On-Demand, Total Access, E-Tearsheet Network.
Next Article:North America Will Be the Strongest Initial Market for Speech Analytics, Followed by EMEA.

Related Articles
Cougar Biotechnology Announces Initiation of Phase I/II Trial for CB7630 (Abiraterone Acetate).
Kamada Receives Final FDA Approval to Commence Phase III Clinical Trials of API with Congenital Emphysema Patients.
New medical titles from Blackwell Publishing.
Kamada and a European Pharmaceutical Company Have Signed a Feasibility Proof MoU Towards the Production of the API Congenital Emphysema Treatment...
The European Medicines Agency Has Approved Kamada's Plan for a Phase 1 Clinical Trial of Alpha 1-Proteinase Inhibitor (API) Respiratory Treatment for...
Aeris Therapeutics Initiates Phase 2 Trial of Biologic Lung Volume Reduction.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters